1. Introduction: Viral Fossils in Our Genome -
Our genomes are strange archives—nearly half of the human DNA isn't “ours” in the traditional sense but originates from ancient viruses. These remnants, known as Human Endogenous Retroviruses (HERVs) and other Transposable Elements (TEs), were once dismissed as “junk” DNA. But modern science is revealing them to be anything but irrelevant.
Recent breakthroughs show that these viral relics are active players—regulating genes, influencing immunity, and even holding therapeutic potential in diseases like cancer, neurodegeneration, and beyond.
---
2. From Junk DNA to Regulatory Gold
For decades, TEs and HERVs were labeled “junk,” yet a groundbreaking study published in Science Advances (July 2025) uncovered that nearly half of the human genome consists of TEs, many sourced from ancient viruses. A focused investigation on one family—MER11, particularly the youngest subgroup MER11_G4—revealed their transcription factor binding sites can actively switch on genes in stem and early neural cells .
Key takeaway: These elements helped orchestrate early development. With tools like CRISPR, researchers are now able to probe how these viral sequences sculpt gene expression—opening possibilities to manipulate them for therapeutic effects.
---
3. HERVs and Immunity: Ancient Allies
Long before modern vaccines, our immunity co-evolved with viruses. HERVs have been co-opted into human physiology. For example, MER41—a viral remnant—helps activate immune cells during an attack by pathogens .
Further, ERV-K Rec proteins boost innate antiviral responses, and viral RNAs derived from HERVs trigger Type I interferon pathways through receptors like TLR3, RIG-I, and others . This suggests that HERVs are not just passive DNA—they are immunological memory built into our genes.
---
4. Cancer and Viral Mimicry: Turning Foes Into Targets
The interplay of HERVs and cancer is compelling:
In kidney cancer (clear cell renal cell carcinoma), dormant viral genes can be reactivated due to mutations. These viral proteins are displayed on tumor cells, flagging the immune system to attack—an insight that could power novel immunotherapies .
Researchers at CU Boulder uncovered that HERV-derived sequences (e.g., LTR10) act as switches turning on oncogenic pathways like MAP-kinase in cancers such as lung and colon. Silencing them with CRISPR deactivates nearby cancer genes and enhances treatment efficacy .
Another HERV—HERV-E—is selectively expressed in many clear cell kidney cancers yet not in normal tissue. Scientists have crafted TCR-engineered T cells targeting HERV-E antigens, with a phase I clinical trial showing initial promise and safety .
Additionally, HERV-K and HERV-H envelope proteins act as tumor-associated antigens in several cancers, potentially triggering strong T-cell responses .
Thus, ancient viral elements may make tumor cells more visible to the immune system—and therapies targeting them could be transformative.
---
5. Autoimmunity, Neurodegeneration, and Epigenetic Failure
HERVs are normally locked down through epigenetic mechanisms like DNA methylation and histone modification. But when these controls break down, HERV activation can contribute to disease:
In Multiple Sclerosis (MS) and Amyotrophic Lateral Sclerosis (ALS), immune-dysregulated HERVs may trigger inflammation and neurodegeneration .
HERV-Fc1 hypomethylation is linked to MS; in ALS, TDP-43 protein dysfunction leads to HERV-K de-repression, furthering disease progression .
Therapeutic Hope: Drugs targeting HERVs are emerging. Temelimab (also known as GNbAC1)—a monoclonal IgG4 antibody against HERV-W Env protein—has progressed to phase II trials in MS. It demonstrates safety, reduced brain lesions, and remyelination in models . Broader reviews support targeting HERVs in neurodegeneration using epigenetic and immunologic strategies .
---
6. Aging and Cellular Senescence: Viral Rescue or Sabotage?
Emerging evidence suggests that during aging, HERVs awaken. A 2023 study found activation of HERV-K (HML-2) in senescent cells—these retroviral-like particles then propagate aging signals to neighboring cells. Neutralizing them reversed aging markers in cells and tissues .
Thus, HERVs may be drivers of aging—but also therapeutic targets to slow or reverse age-related decline.
---
7. Neuropsychiatric Links: Mental Health and Genetic Risks
A study from King’s College London correlated certain HERV activity with higher genetic risk for depression, schizophrenia, and bipolar disorder. Altered HERV gene activity in nearly 800 postmortem brains was linked to these mental health conditions, suggesting a regulatory role in brain function and disease .
Though explorative, this research raises the intriguing possibility that modulating HERVs could impact psychiatric disorders.
---
8. Summary: Transformational Potential Across Fields
Domain Viral Element Therapeutic Angle
Development MER11 TEs activating developmental genes Future gene regulation therapies
Immunity MER41, HERV-K RNAs signaling immune response Vaccine or immune modulatory targeting
Oncology LTR10, HERV-E, HERV-K antigens Immunotherapy (TCR, CAR-T, checkpoint enhancers)
Neurology HERV-W, HERV-K activation Antibody (temelimab), epigenetic drugs
Aging HERV-K particles in senescence Anti-aging, senolytic therapies
Psychiatry HERV activity in psychiatric risk Novel neuropsychiatric targets
---
9. Challenges and Future Directions
The therapeutic excitement is tempered by real challenges:
Many HERVs are silenced under normal conditions, so targeted activation or suppression must be tissue- and context-specific .
HERVs are also involved in normal physiology, especially in early development or the placenta—indiscriminate targeting could cause collateral damage .
Modulating HERVs could inadvertently trigger autoimmunity, since immune tolerance to viral proteins is incomplete .
Therapies like TCR/CAR T cells must improve persistence, specificity, and HLA coverage for effective clinical translation .
Most research is preclinical or in early trials; extensive validation lies ahead.
---
10. The Vision Ahead: Viruses Within, Weapons Without?
What if we begin to see HERVs not as genomic debris, but latent partners?
Cancer vaccines could be engineered using HERV antigens to awaken robust anti-tumor immunity.
Neurological diseases might be treated with antibodies like temelimab, or epigenetic drugs resetting HERV control.
Age-related decline could be combated by neutralizing senescence-inducing viral elements.
Psychiatric conditions may be better understood—and eventually treated—by mapping HERV-driven regulatory disruptions.
---
11. Closing Thoughts
The ancient viral sequences embedded in our DNA are not junk—they are history, regulators, and potentially powerful levers for therapy.
Harnessing them safely and effectively could transform medicine across cancer, neurology, aging, immunity, and mental health.
The medical revolution hidden in our genomes has only just begun to unfold.
---
